ArticleJournal of pharmaceutical health care and sciences2026
Impact of co-administration of proton pump inhibitors on efficacy and safety of oral semaglutide in patients with type 2 diabetes: a single-center retrospective study.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral semaglutide, a glucagon-like peptide-1 receptor agonist, improves glycemic control and reduces body weight in patients with type 2 diabetes. Although proton pump inhibitors (PPIs) have been reported to slightly increase the absorption of oral semaglutide, the impact of 24-week co-administration of PPIs on clinical efficacy and safety remains unclear.
methodsThis retrospective study included patients with type 2 diabetes who initiated treatment with oral semaglutide between March 2021 and August 2024. The primary outcome was the change in the HbA1c at week 24. The secondary outcomes included the change in body weight and discontinuation of oral semaglutide due to gastrointestinal adverse events at week 24. Patients were divided into two groups according to PPI co-administration. Propensity score matching was performed to balance the baseline characteristics between the groups. Changes in HbA1c and body weight were analyzed using a linear mixed-effects model, and discontinuation rates were compared using Fisher's exact test.
resultsAmong the 114 eligible patients, 30 received concomitant PPIs. After propensity score matching, 27 patients were included in each group. At week 24, the estimated mean change in HbA1c and body weight (95% confidence interval) was - 1.0% (-1.3 to -0.6) and - 1.4 kg (-2.6 to -0.3) in the PPI group and - 0.6% (-0.8 to -0.3) and - 1.8 kg (-2.5 to -1.0) in the non-PPI group. There were no statistically significant group-by-time interactions for HbA1c and body weight (P for interaction = 0.097 and 0.431, respectively). Discontinuation due to gastrointestinal adverse events did not differ significantly between the groups (25.9% vs. 18.5%).
conclusions24-week co-administration of PPIs may not significantly affect the glycemic efficacy, weight reduction, or gastrointestinal tolerability of oral semaglutide. These findings suggest that the co-administration of PPIs is unlikely to meaningfully impact the clinical efficacy or tolerability of oral semaglutide in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.